FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200278074> ?p ?o ?g. }

• W4200278074 endingPage "396" @default.
• W4200278074 startingPage "388" @default.
• W4200278074 abstract "To compare prostate cancer (PCa) detection rate of transperineal template-guided saturation prostate biopsy (SBx) and multiparametric magnetic resonance imaging (mpMRI)/transrectal ultrasound fusion guided targeted biopsy (TBx). MATERIALS AND METHODS: We prospectively enrolled 392 men who underwent SBx and TBx in case of suspicious lesions from November 2016 to October 2019. Triggers for a biopsy were an elevated prostate-specific antigen (PSA) and/or positive digital rectal examination and only treatment naïve patients without a previous diagnosis of PCa were included. Study inclusion occurred before biopsy and a prebiopsy mpMRI was available in all men. SBx were taken from 20 different locations according to the modified Barzell zones. The primary endpoint was the detection rate of clinically significant PCa (csPCa) and insignificant PCa (ciPCa) by SBx and/or TBx by comparing the two methods alone and in combination. Additional TBx were taken for any prostate imaging-reporting and data system (PI-RADS) lesion ≥3 seen on the mpMRI. csPCa was defined as any Gleason score ≥7 and ciPCa as Gleason score 6.A total of 392 men with a median age of 64 years (interquartile range [IQR]: 58-69), a median PSA of 7.0 ng/ml (IQR: 4.8-10.1) were enrolled. Overall, PCa was found in 200 (51%) of all biopsied men, with 158 (79%) being csPCa and 42 (21%) ciPCa. A total of 268 (68%) men with a suspicious mpMRI and underwent a combined TBx and SBx, of whom csPCa was found in 139 (52%). In this subgroup, 116/139 (83%) csPCa would have been detected by TBx alone, and an additional 23 (17%) were found by SBx. Men with a negative mpMRI (PI-RADS < 3, n = 124, 32%) were found to have csPCa in 19 (15%) cases. In patients with a negative mpMRI in combination with a PSA density <0.1 ng/ml2 , only 8% (3/36) had csPCa. If only TBx would have been performed and all men with a negative mpMRI would not have been biopsed, 42/158 (27%) of csPCa would have been missed, and 38/42 (90%) ciPCa would have not been detected. On multivariable analysis, significant predictors of csPCa were increasing PSA (odds ratio, OR: 1.07 [95% confidence interval, CI: 1.03-1.11]), increasing age (OR: 1.07 [95% CI: 1.03-1.11]), PI-RADS score ≥ 3 (OR: 6.49 [95% CI: 3.55-11.89]), and smaller prostate volume (OR: 0.96 [95% CI: 0.95 -0.97] (p < 0.05 for all parameters).In comparison to SBx, TBx alone detects csPCa in only ¾ of all men with a positive mpMRI lesion. Thus, systematic biopsies in addition to TBx have to be considered at least in some who undergo a prostate biopsy. In men with a negative mpMRI, SBx still detects 15% csPCa, but similarly overdetecting ciPCa. According to our results, low PSA density and negative mpMRI findings could be used to decide which men can safely avoid biopsy." @default.
• W4200278074 created "2021-12-31" @default.
• W4200278074 creator A5001577685 @default.
• W4200278074 creator A5005455641 @default.
• W4200278074 creator A5010007720 @default.
• W4200278074 creator A5011584203 @default.
• W4200278074 creator A5027653417 @default.
• W4200278074 creator A5028663673 @default.
• W4200278074 creator A5037978174 @default.
• W4200278074 creator A5042503091 @default.
• W4200278074 creator A5042519654 @default.
• W4200278074 creator A5047129990 @default.
• W4200278074 creator A5054516841 @default.
• W4200278074 creator A5061661997 @default.
• W4200278074 creator A5067287697 @default.
• W4200278074 creator A5068214093 @default.
• W4200278074 date "2021-12-16" @default.
• W4200278074 modified "2023-10-17" @default.
• W4200278074 title "Prostate cancer detection rate in men undergoing transperineal template‐guided saturation and targeted prostate biopsy" @default.
• W4200278074 cites W1827911007 @default.
• W4200278074 cites W2002327210 @default.
• W4200278074 cites W2016809511 @default.
• W4200278074 cites W2022929878 @default.
• W4200278074 cites W2070348309 @default.
• W4200278074 cites W2082328647 @default.
• W4200278074 cites W2086826587 @default.
• W4200278074 cites W2115895082 @default.
• W4200278074 cites W2142775721 @default.
• W4200278074 cites W2144443552 @default.
• W4200278074 cites W2148451911 @default.
• W4200278074 cites W2189540889 @default.
• W4200278074 cites W2230472428 @default.
• W4200278074 cites W2395925941 @default.
• W4200278074 cites W2549680677 @default.
• W4200278074 cites W2577453388 @default.
• W4200278074 cites W2612474452 @default.
• W4200278074 cites W2735211627 @default.
• W4200278074 cites W2756318850 @default.
• W4200278074 cites W2764317271 @default.
• W4200278074 cites W2778234364 @default.
• W4200278074 cites W2788973951 @default.
• W4200278074 cites W2793905111 @default.
• W4200278074 cites W2889616788 @default.
• W4200278074 cites W2900548778 @default.
• W4200278074 cites W2901859788 @default.
• W4200278074 cites W2925827767 @default.
• W4200278074 cites W2952030907 @default.
• W4200278074 cites W2971435390 @default.
• W4200278074 cites W3010331388 @default.
• W4200278074 cites W3183065453 @default.
• W4200278074 cites W4200278074 @default.
• W4200278074 doi "https://doi.org/10.1002/pros.24286" @default.
• W4200278074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34914121" @default.
• W4200278074 hasPublicationYear "2021" @default.
• W4200278074 type Work @default.
• W4200278074 citedByCount "12" @default.
• W4200278074 countsByYear W42002780742021 @default.
• W4200278074 countsByYear W42002780742022 @default.
• W4200278074 countsByYear W42002780742023 @default.
• W4200278074 crossrefType "journal-article" @default.
• W4200278074 hasAuthorship W4200278074A5001577685 @default.
• W4200278074 hasAuthorship W4200278074A5005455641 @default.
• W4200278074 hasAuthorship W4200278074A5010007720 @default.
• W4200278074 hasAuthorship W4200278074A5011584203 @default.
• W4200278074 hasAuthorship W4200278074A5027653417 @default.
• W4200278074 hasAuthorship W4200278074A5028663673 @default.
• W4200278074 hasAuthorship W4200278074A5037978174 @default.
• W4200278074 hasAuthorship W4200278074A5042503091 @default.
• W4200278074 hasAuthorship W4200278074A5042519654 @default.
• W4200278074 hasAuthorship W4200278074A5047129990 @default.
• W4200278074 hasAuthorship W4200278074A5054516841 @default.
• W4200278074 hasAuthorship W4200278074A5061661997 @default.
• W4200278074 hasAuthorship W4200278074A5067287697 @default.
• W4200278074 hasAuthorship W4200278074A5068214093 @default.
• W4200278074 hasBestOaLocation W42002780742 @default.
• W4200278074 hasConcept C119060515 @default.
• W4200278074 hasConcept C121608353 @default.
• W4200278074 hasConcept C126322002 @default.
• W4200278074 hasConcept C126838900 @default.
• W4200278074 hasConcept C126894567 @default.
• W4200278074 hasConcept C2775934546 @default.
• W4200278074 hasConcept C2776235491 @default.
• W4200278074 hasConcept C2780101318 @default.
• W4200278074 hasConcept C2780192828 @default.
• W4200278074 hasConcept C2781217009 @default.
• W4200278074 hasConcept C71924100 @default.
• W4200278074 hasConceptScore W4200278074C119060515 @default.
• W4200278074 hasConceptScore W4200278074C121608353 @default.
• W4200278074 hasConceptScore W4200278074C126322002 @default.
• W4200278074 hasConceptScore W4200278074C126838900 @default.
• W4200278074 hasConceptScore W4200278074C126894567 @default.
• W4200278074 hasConceptScore W4200278074C2775934546 @default.
• W4200278074 hasConceptScore W4200278074C2776235491 @default.
• W4200278074 hasConceptScore W4200278074C2780101318 @default.
• W4200278074 hasConceptScore W4200278074C2780192828 @default.
• W4200278074 hasConceptScore W4200278074C2781217009 @default.
• W4200278074 hasConceptScore W4200278074C71924100 @default.
• W4200278074 hasIssue "3" @default.

• next